动脉内心介质厚度,传统风险因素和蛋白质之间的关联
NPJ cardiovascular health
|March 3, 2026
概括
传统的心血管风险因素,如LDL胆固醇,BMI和糖尿病,因果关系地影响着动脉内心介质厚度 (IMT). RABEPK蛋白可能是减少IMT的治疗标.
科学领域:
- 心血管疾病研究研究
- 遗传学和基因组学 遗传学和基因组学
- 生物标志物发现发现
背景情况:
- 动脉内心介质厚度 (IMT) 是亚临床动脉样硬化的关键指标.
- 了解心血管风险因素对IMT的因果作用对于预防策略至关重要.
研究的目的:
- 评估传统心血管风险因素对IMT的因果影响.
- 确定与IMT相关的蛋白质,并探索它们的因果关系.
主要方法:
- 利用来自5万多名参与者的英国生物库数据进行IMT测量.
- 分析了6328个人的血蛋白水平.
- 使用孟德尔随机化 (MR) 分析来推断因果关系.
主要成果:
- 观察性分析将较高的LDL胆固醇,BMI,糖尿病和SBP与增加的IMT联系在一起.
- MR证实了LDL胆固醇,BMI和糖尿病对IMT的因果作用.
- 在MR分析中,五种蛋白质 (BCAM,NTproBNP/NPPB,RABEPK,ACAN,FN1) 与IMT存在关联,RABEPK显示出一致的方向关系.
结论:
- 核磁共振分析支持LDL胆固醇,BMI,糖尿病,SBP和IMT之间的因果关系.
- RABEPK蛋白被确定为IMT管理的潜在治疗标,需要进一步调查.
更多相关视频
13:45A Method to Study the Correlation Between Local Collagen Structure and Mechanical Properties of Atherosclerotic Plaque Fibrous Tissue
Published on: November 11, 2022
3.7K
06:04Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
1.7K
相关概念视频
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
769
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
769
Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
961
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
961
Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
